Anti BCMA chimeric antigen receptor natural killer cell therapy - Hangzhou Cheetah Cell Therapeutics
Alternative Names: Anti-BCMA-CAR-NK-cell-therapyLatest Information Update: 31 Mar 2023
At a glance
- Originator Hangzhou Cheetah Cell Therapeutics
- Developer Hangzhou Cheetah Cell Therapeutics; Zhejiang University
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Multiple myeloma
Most Recent Events
- 01 Feb 2023 Clinical trials in Multiple myeloma (In adults, In the elderly, Second-line therapy or greater) in China (Parenteral) (NCT05747586)